1. Home
  2. Browse
  3. HRA016085
HRA016085
   HRA016085.xlsx
Title:
Immunoglobulin NGS enhance residual disease detection and prognosis in pediatric Ph+ acute lymphoblastic leukemia
Release date:
2026-01-15
Description:
In pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ B-ALL), the clinical value of highly sensitive minimal residual disease (MRD) detection by immunoglobulin next-generation sequencing (Ig-NGS), and its role for tracking clonal evolution, remains inadequately characterized. In this study, we evaluated MRD in a cohort of pediatric Ph+ B-ALL patients using Ig-NGS in parallel with conventional methods, including Fow cytometry (FCM) and BCRABL reverse transcription polymerase chain reaction (RT-PCR). Malignant clonal burden at diagnosis, MRD kinetics, and immunoglobulin heavy chain (IGH) clonal evolution were analyzed for their prognostic relevance.
Data Accessibility:   
Controlled access Request Data
BioProject:
PRJCA055449
Study type:
Disease Study
Disease name:
lymphoblastic leukemia
Data Access Committee

For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.


DAC NO.:
HDAC008004
DAC name:
Ph+ ALL
Contact person:
Zhang Li
Email:
zhangli1@ihcams.ac.cn
Description:
Ph+ ALL BCR sequencing
Individuals & samples
Files
Request Data
Submitter:   Chang lixian / changlixian@ihcams.ac.cn
Organization:   State Key Laboratory of Experimental Hematology, Institute of Hematology and Hospital of Blood Diseases
Submission date:   2026-01-12
Requests:   -